Summary-Factors that affect outcome in pediatric heart diseases such as dilated cardiomyopathy are often difficult to define because of the rarity of disease. To study the potential importance of factors at presentation and at listing for heart transplantation in children with dilated cardiomyopathy on outcome, we analyzed data from 2 large pediatric registries: the Pediatric Cardiomyopathy Registry and the Pediatric Heart Transplant Study. In the merged data set, there were 261 children with dilated cardiomyopathy. Among the factors studied were age, duration of illness, sex, race, ventricular geometry, and the clinical or histological diagnosis of myocarditis at presentation. We found that death while waiting was associated with ventilator use and older age at listing. A shorter duration of illness was associated with a more urgent listing status (United Network for Organ Sharing status 1). Death after transplantation was associated black race and lower left ventricular end-diastolic dimension z score at presentation. We also found that death after transplantation was associated with the diagnosis of myocarditis at presentation (P<0.009). Death while waiting was not associated with the diagnosis of myocarditis, and 97% of children with myocarditis survived to transplantation. Furthermore, the most common cause of death after transplantation in the myocarditis group was acute rejection (17%). This is the first study to show that children with dilated cardiomyopathy and myocarditis have significantly higher posttransplantation mortality compared with children without myocarditis. This finding suggests that preexisting viral infection or inflammation could adversely affect heart allograft survival and has implications for the management of these children before and after heart transplantation in the future.
Conclusions-Mechanical ventilator use and older age at listing predicted death while waiting, whereas nonwhite race, smaller left ventricular dimension, and myocarditis were associated with death after transplantation. Although 97% of children with clinically or biopsy-diagnosed myocarditis at presentation survived to transplantation, they had significantly higher posttransplantation mortality compared with children without myocarditis, raising the possibility that preexisting viral infection or inflammation adversely affects graft survival. 1 
Extracorporeal Membrane Oxygenation for Bridge to Heart Transplantation Among Children in the United States: Analysis of Data From the Organ Procurement and Transplant Network and Extracorporeal Life Support Organization Registry
Summary-Extracorporeal membrane oxygenation (ECMO) has served for >2 decades as the standard of care for US children requiring mechanical support as a bridge to heart transplantation. Unfortunately, objective data on the safety and efficacy of ECMO for this purpose are limited in part because ECMO has never been approved by the Food and Drug Administration for this particular indication. In this study, data from the Extracorporeal Life Support Organization and Organ Procurement Transplant Network registries are combined to describe the efficacy and safety profile of ECMO for a bridge to heart transplantation and to propose objective performance goals that can be used as benchmarks to facilitate Food and Drug Administration approval of emerging miniaturized cardiac assist devices intended to replace ECMO. Among 733 children supported with ECMO as a bridge to heart transplantation since the mid-1990s, fewer than half survived to hospital discharge. Most deaths occurred while the children were on the wait list, but children successfully transplanted also had high posttransplantation mortality, accounting for up to one third of all in-hospital deaths. The risk of death was not uniform across all patient groups and varied by cardiac diagnosis, end-organ dysfunction, and duration of ECMO support. In the objective performance goal cohort, patients with cardiomyopathy had the highest survival to hospital discharge (63%), followed by patients with myocarditis (59%), 2-ventricle congenital heart disease (44%), and 1-ventricle congenital heart disease (33%). These findings suggest that, although ECMO may be effective for short-term circulatory support, it is not reliable for the long-term circulatory support necessary for children awaiting heart transplantation. Most important, these findings indicate that more effective modalities for long-term circulatory support are urgently needed for children.
Conclusions-Although ECMO is effective for short-term circulatory support, it is not reliable for the long-term circulatory support necessary for children awaiting heart transplantation. Fewer than half of patients bridged with ECMO survive to hospital discharge. More effective modalities for chronic circulatory support in children are urgently needed.
Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation
Summary-Cardiac allograft vasculopathy remains the leading cause of morbidity and mortality late after heart transplantation and accounts for a third of all-cause mortality at 5 years. Traditional immunosuppression after cardiac transplantation combining calcineurin inhibitors with mycophenolate mofetil or azathioprine and corticosteroids has improved short-term survival after heart transplantation but has not prevented the development of cardiac allograft vasculopathy. Sirolimus or its derivative, everolimus, has generally been used as a secondary immunosuppressive agent in place of azathioprine or mycophenolate mofetil. Our study is the first long-term comparable serial 3-dimensional intravascular ultrasound and outcome study that demonstrates that early, and even late, conversion from calcineurin inhibitor to sirolimus as a primary immunosuppressive agent may be effective for delaying the progression of cardiac allograft vasculopathy and lumen loss. We show that sirolimus attenuates the rate of intimal hyperplasia and plaque progression in the first years after transplantation. Subsequently, it may delay the characteristic vessel remodeling biphasic response, consisting of early expansion and late constriction of vessel volume (external elastic membrane). Most important, our findings suggest that a calcineurin inhibitor-free regimen not only is safe and well tolerated but also may be effective in decreasing cardiac allograft vasculopathy-related adverse outcomes and all-cause mortality, although prospective clinical trials are required to recommend sirolimus as a first-choice primary immunosuppressant.
Conclusions-Substituting calcineurin inhibitor with sirolimus as primary immunosuppressant attenuates long-term cardiac allograft vasculopathy progression and may improve long-term allograft survival owing to favorable coronary remodeling. Because of the lack of randomization and retrospective nature of our analysis, the differences in outcome should be interpreted cautiously, and prospective clinical trials are required. 
Simple Score to Assess the Risk of Rejection After Orthotopic Heart Transplantation
Summary-In this study, we have derived and validated a risk score for rejection after orthotopic heart transplantation. We used data from the United Network for Organ Sharing registry on >14 000 orthotopic heart transplantation recipients to achieve this goal. The 13-point risk score incorporated 4 variables (age, race, sex, and HLA matching) and was highly predictive of drug-treated rejection in the first posttransplantation year. Predicted rates of 1-year rejection ranged from 16.2% in those with a score of 0 to 50.7% in those with a score of 13. In weighted regression analysis, there was a strong correlation between these predicted rates based on the derivation cohort and actual, observed rejection rates in the validation cohort (r 2 =0.96, P<0.001). Logistic regression analysis also demonstrated this significant association (odds ratio, 1.13; P<0.001). The c index for the score was equivalent in the derivation and validation cohorts (c=0.67). This highly predictive, simple-to-calculate risk score has potential utility in tailoring immunosuppressive regimens for orthotopic heart transplantation recipients and in research stratification.
Conclusions-This novel 13-point risk score is highly predictive of clinically significant rejection episodes within 1 year of orthotopic heart transplantation. It has potential utility in tailoring immunosuppressive regimens and in research stratification in orthotopic heart transplantation. 4 
Persistent Racial Disparities in Survival After Heart Transplantation
Summary-Racial and ethnic minority patients have poorer clinical outcomes in many forms of heart disease. We assessed outcomes among 39 075 initial heart transplant recipients categorized by racial and ethnic groups. Nonwhite transplant recipients had a higher clinical risk profile at baseline than white recipients. Black heart transplant recipients had 34% higher mortality than whites, which remained significant even after adjustment for recipient, transplant, and socioeconomic factors. Mortality for other minority groups was not different from that of whites. Black patients were more likely to die of causes associated with underimmunosuppression (cardiovascular causes or graft failure) and less likely to die of causes associated with overimmunosuppression (infection or malignancy). Despite the increased attention to mortality disparities present among black patients-in health care broadly and cardiovascular care specifically-the disparity in mortality between blacks and whites after heart transplantation remained essentially unchanged over time. Future investigation is needed into potential causes of the higher mortality among black heart transplant recipients, which appears to be due to less effective immunosuppression. Novel methods of assessing immunosuppression, from both immunologic and sociomedical perspectives, may be important.
Conclusions-Black heart transplant recipients have had persistently higher mortality than whites recipients over the past 2 decades, perhaps because of a higher rate of graft failure. 
Racial and Ethnic Differences in Wait-List Outcomes in Patients Listed for Heart Transplantation in the United States
Summary-Although racial differences in long-term survival after heart transplant are well known, there is limited information regarding racial/ethnic differences in mortality among those listed for a heart transplant. In this study, the authors compared wait-list and early posttransplant mortality among white, black, and Hispanic adult patients listed in the United States for heart transplant between July 2006 and September 2010. Of 10 377 patients analyzed, 71% were white, 21% were black, and 8% were Hispanic. Black and Hispanic patients were more likely to be listed with higher urgency in comparison with white patients. Overall, 10.5% of white, 11.6% of black, and 13.4% of Hispanic candidates died on the wait-list or became too sick for a transplant (removed from the list because of deterioration) within 1 year of listing. After adjusting for baseline risk factors, Hispanic patients were at 51% higher risk of dying on the wait list or becoming too sick for a transplant in comparison with white patients. Black patients were not at higher risk of dying on the waitlist. Among patients who received a heart transplant, posttransplant in-hospital mortality was 53% higher in black recipients in comparison with white recipients after adjusting for other risk factors at the time of transplant, but posttransplant in-hospital mortality was not different in Hispanic recipients in comparison with white recipients. The authors conclude that these gaps in wait-list and posttransplant outcomes among racial/ethnic groups merit further investigation.
Conclusions-Hispanic patients listed for heart transplant in the United States appear to be at higher risk of dying on the wait-list or becoming too sick for a transplant in comparison with white patients. Black patients are not at higher risk of wait-list mortality, but they have higher early posttransplant mortality.
Transplantation in Children With Dilated Cardiomyopathy: Results From the Pediatric Cardiomyopathy Registry
Summary-Prior studies of outcomes for children with dilated cardiomyopathy (DCM) have used a composite end point of death and cardiac transplantation and may have missed identifying predictive factors differentially affecting outcomes, which affect the transplantation listing process. Using competing risk analysis, this study found that at the time of DCM diagnosis, the presence of congestive heart failure, echocardiographic evidence of more severe disease, and increased age at diagnosis predicted worse outcomes, with certain key differences between etiologic groups. For children with idiopathic disease, diagnosis after 6 years of age, congestive heart failure, decreased left ventricular (LV) fractional shortening, increased LV end-diastolic dimension, and decreased height-for-age predicted worse outcomes. Increased LV dilation was predictive of use of transplantation but not of mortality in idiopathic DCM, calling into question the importance of this factor in the decision to list for transplantation. Routine height measurement could highlight those with idiopathic DCM and lower height-for-age z scores who might require more urgent consideration for transplantation listing. For children with neuromuscular disease, decreased LV fractional shortening predicted death or transplantation, whereas increased LV end-diastolic dimension predicted transplantation but not death. For children with myocarditis, older age at diagnosis, congestive heart failure, and increased LV end-diastolic dimension predicted death or transplantation. These results suggest that the etiology of DCM modifies the importance of particular predictive factors. The ability to predict failed medical management may improve if the etiology of the cardiomyopathy can be established earlier. Additionally, analyses of registry data in this manner allow the postulation of predictive algorithms of clinical outcomes.
Conclusions-Risk factors for death and transplantation in children varied by DCM etiology. For idiopathic DCM, increased LV end-diastolic dimension was associated with increased transplantation risk but not mortality. Conversely, short stature was significantly related to death but not transplantation. These findings may present an opportunity to improve the transplantation selection algorithm. 
Statins and the Risk of Cancer After Heart Transplantation
Summary-Although newer immunosuppressive agents have lowered the incidence of malignancies after transplantation, cancer remains a leading cause of death late after heart transplantation. Because statins are immunomodulatory drugs and reduce the incidence of rejection and improve survival after cardiac transplantation, the present study investigated whether statin therapy impacts cancer risk as well as cancer-free and total mortality in heart transplant recipients. During follow-up, a malignancy was diagnosed in 108 patients (42%). Interestingly, the cumulative incidence of any malignancy was reduced in patients receiving a statin 8 years after transplantation (34% versus13%, P=0.003), and the benefit persisted at the 10-year and 12-year follow-up. In addition, statin use was associated with improved cancer-free and overall survival (both P<0.0001). Statins reduced the hazard of occurrence of any malignancy by 67% (hazard ratio, 0.33; P<0.0001). A Cox regression model that analyzed the time to tumor formation with or without statin therapy, adjusted for age, male sex, type of cardiomyopathy, and immunosuppressive therapy (including switching to mTOR [mammalian target of rapamycin] inhibitors or tacrolimus), demonstrated a decreased hazard for tumor formation in the statin group. Thus, in spite of limitations in adjusting for all potential confounders over a follow-up period of up to 25 years, during which factors related to the era of transplantation (such as overall intensity of immunosuppression and use of azathioprine) might have changed, the results of the present study suggest that statin use is associated with a substantial reduction of cancer risk and all-cause mortality in heart transplant recipients. Whether these benefits of statins are specific for heart transplant recipients who are at particularly high risk of cancer or can be extrapolated to all patients undergoing long-term immunosuppressive therapy (particularly with tacrolimus and mTOR inhibitors) needs to be confirmed in long-term randomized clinical trials.
Conclusions-Although it is not possible to adjust for all potential confounders because of the very long follow-up period, this registry suggests that statin use is associated with improved cancer-free and overall survival after cardiac transplantation. These data will need to be confirmed in a prospective trial. Summary-This study investigated a small, intrapericardially positioned, continuous-flow centrifugal pump, the HeartWare ventricular assist device, as a bridge to heart transplantation. The course of 140 investigational pump patients was compared with that of 499 patients implanted contemporaneously as a bridge to transplantation with commercially available ventricular assist devices and enrolled in a national registry. Perioperative mortality for the investigational pump group was 1%, and Kaplan-Meier estimated survival at 1 year was 90%. The primary outcome, defined as survival on the originally implanted device, transplantation, or explantation for ventricular recovery at 180 days, occurred in 92.0% of investigational pump patients and 90.1% of controls, establishing the noninferiority of the investigational pump. At 6 months, 6-minute walk test distance improved by 152 m, and both disease-specific and global quality-of-life scores improved substantially. The adverse event profile with the investigational pump was notable for relatively low rates of gastrointestinal bleeding and bleeding requiring surgery, with other adverse event rates similar to those reported previously for continuous-flow pumps in bridge-to-transplantation trials. Quality-of-life and functional capacity improvements were much larger than seen with any drug or device therapy for advanced heart failure and similar to those obtained with cardiac transplantation. This study demonstrates the excellent outcomes that are now achievable with the present generation of small, continuous-flow pumps.
Conclusions-A small, intrapericardially positioned, continuousflow, centrifugal pump was noninferior to contemporaneously implanted, commercially available ventricular assist devices. Functional capacity and quality of life improved markedly, and the adverse event profile was favorable. 
Listing and Transplanting Adults With Congenital Heart Disease
Summary-An increasing number of patients with congenital heart disease (CHD) are reaching adulthood. These patients, often with systemic right ventricles or long-standing valvular disease, are at increased risk for the development of heart failure and may require heart transplantation. These adult patients with CHD may need to be managed differently from non-CHD patients, but few studies have specifically examined their outcomes both on the waiting list and after transplantation. A better understanding of the differences between CHD and non-CHD patients may enable improvements in the outcomes of this increasingly important population. In this study, we demonstrate that patients with CHD are different from those without CHD: They are younger and have fewer comorbidities but have higher early posttransplantation mortality. Mechanical circulatory assistance is not associated with improved survival among CHD patients on the waiting list. The increasingly common transplantation of patients with complex CHD may result in particularly high posttransplantation mortality, and centers performing these transplantations should proceed with caution. Collection of data specific to the CHD population, including accurate congenital diagnoses, is essential to better understanding and improving the outcomes with transplantation in this population.
Conclusions-Adults with CHD have high 30-day mortality but better late survival after heart transplantation. Mechanical circulatory assistance does not improve waiting list survival in these patients. This may be due to a combination of highly complex reoperative surgery and often poor preoperative systemic health.
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Identification and Classification of Acute Cardiac Rejection by Intragraft Transcriptional Profiling
Summary-Surveillance for acute cellular rejection after heart transplantation relies on histological evaluation of serial endomyocardial biopsies, an approach limited by sampling error and interobserver variations in the interpretation even when performed by the most experienced pathologist. This clinical area would benefit from technologies requiring fewer biopsies and more consistent sampleto-sample information. We have used intragraft transcriptional profiling to explore a possible alternative approach for diagnosing acute rejection. Using only 1 endomyocardial biopsy, our results show a consistent expression pattern between similar grades of acute rejection and distinctly different expression patterns between different rejection grades that was not influenced by variable section-tosection histology. Furthermore, the expression pattern distinguished grade 1B from all others and was thus more in accordance with the original International Society for Heart and Lung Transplantation grading scale (1990) than with the revised rejection grading system (2005 International Society for Heart and Lung Transplantation guidelines) that combines several rejection grades. These observations raise important clinical implications for acute cellular rejection surveillance: (1) transcriptional profiling may provide a more uniform read-out than histological evaluation, with less subjective section-to-section variability; (2) if confirmed in a larger sample set and a conclusive transcriptome identified for each rejection grade, transcriptional profiling can be an additional and complementary tool for diagnosing acute rejection, which can ultimately change the clinical practice to collecting fewer biopsies to diagnose rejection; and (3) the consistent expression pattern for grade 1B suggests that the International Society for Heart and Lung Transplantation grading system should be reevaluated to limit the combining of tissues with different underlying processes, taking into account new insights from advanced technologies.
Conclusions-The gene expression similarities and differences identified here in different acute rejection settings have the potential to revise the clinical perspective on acute graft rejection, pending the results of larger studies.
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Loss of Myeloid Related Protein-8/14 Exacerbates Cardiac Allograft
Summary-Graft arterial disease (GAD) limits long-term survival in cardiac transplant recipients. GAD shares some pathophysiological features with conventional atherosclerosis; APCs present alloantigens (eg, antigens on donor ECs) or autoantigens (eg, oxidized lowdensity lipoprotein cholesterol) to T cells, initiating differentiation and activation of T cells, B cells, and inflammatory cell responses with costimulatory signaling. Nevertheless, there are important differences in the pathology and distribution of these diseases. Although hyperlipidemia, a well-established risk factor for conventional atherosclerosis, is common after transplantation, GAD lesions tend to be lipid poor. GAD involves large and medium-sized vessels and the microvasculature and affects the media, adventitia, and intima. MRP-14 deficiency can attenuate wire injury-induced vascular lesions and atherosclerotic lesions in atherogenic animals. In contrast, the present study demonstrates that recipient MRP-14 deficiency exacerbates allograft vasculopathy. This study examined the effect of MRP-14 deficiency on parenchymal rejection and GAD after MHC class IImismatched murine heart transplantation without immunosuppression. Clinical application requires future studies evaluating the effects of MRP-14 expression in the setting of immunosuppressive therapy. 
Conclusions-Our
Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial
Summary-Kidney transplant recipients experience an excess risk of cardiovascular disease and elevated total homocysteine concentrations. Although observational studies of patients with chronic kidney disease suggest that increased homocysteine is a risk factor for cardiovascular disease, the clinical benefit of lowering total homocysteine levels in kidney transplant recipients is unknown. We randomized 4110 stable kidney transplant recipients to a multivitamin that included either a high dose (n=2056) or low dose (n=2054) of folic acid, vitamin B6, and vitamin B12 to determine whether decreasing total homocysteine concentrations reduced the rate of arteriosclerotic cardiovascular disease outcomes. After a follow-up of 4.0 years, the high-dose multivitamin reduced homocysteine levels but not the rates of the pooled arteriosclerotic outcome (n=547 total events; hazards ratio [95% confidence interval]=0.99 [0.84 to 1.17]), secondary outcomes of all-cause mortality (n=431 deaths; 1.04 [0.86 to 1.26]), or dialysis-dependent kidney failure (n=343 events; 1.15 [0.93 to 1.43]) compared to the low-dose multivitamin. We concluded that treatment with a high-dose folic acid, B6, and B12 multivitamin in kidney transplant recipients does not reduce cardiovascular disease outcome, all-cause mortality, or dialysis-dependent kidney failure despite significant reduction in homocysteine level.
Conclusions-Treatment with a high-dose folic acid, B6, and B12 multivitamin in kidney transplant recipients did not reduce a composite cardiovascular disease outcome, all-cause mortality, or dialysis-dependent kidney failure despite significant reduction in homocysteine level.
Donor Simvastatin Treatment Abolishes Rat Cardiac Allograft Ischemia/ Reperfusion Injury and Chronic Rejection Through Microvascular Protection
Summary-Ischemia/reperfusion injury after heart transplantation may result in primary graft dysfunction or initiation of fibroproliferative cascades, leading to the development of cardiac fibrosis, allograft arteriosclerosis, and compromised long-term survival. Vascular dysfunction, including permeability and perfusion disturbances, plays a central role in ischemia/reperfusion injury. Statins are widely used to lower cholesterol levels, but they also have cholesterol-independent pleiotropic effects through Rho GTPase inhibition. We used heterotopic rat heart transplantation models to investigate whether a single dose of simvastatin administered to cardiac allograft donors perorally 2 hours before graft removal protects the cardiac allograft through direct vasculoprotective effects. Donor simvastatin treatment abolished cardiac allograft ischemia/reperfusion injury by preventing the no-reflow phenomenon and reducing vascular permeability, inflammation and cardiomyocyte injury. These early vasculoprotective and cardioprotective effects were mirrored with sustained antiinflammatory, antifibrotic, and antiarteriosclerotic effects in a chronic rejection heart transplantation model. Mechanistic studies indicated that donor simvastatin treatment decreased cardiac allograft microvascular endothelial cell and pericyte RhoA activation, modified the expression of vasculoprotective genes, and improved endothelial barrier function. In contrast to donor simvastatin treatment, recipient simvastatin treatment did not protect against ischemia/reperfusion injury. In vitro studies also showed that simvastatin decreased endothelialmesenchymal transition, a recently characterized mechanism participating in cardiac fibrosis. Collectively, our results highlight the rapid vasculoprotective effects of simvastatin during ischemia/reperfusion injury and suggest donor simvastatin as a novel, clinically feasible strategy to protect cardiac allografts.
Conclusions-Our results demonstrate that donor simvastatin treatment prevents microvascular endothelial cell and pericyte dysfunction, ischemia/reperfusion injury, and chronic rejection and suggest a novel, clinically feasible strategy to protect cardiac allografts. Summary-Cardiac cell replacement therapies may significantly extend current therapeutic options for various cardiac diseases. The recently developed induced pluripotent stem cells are considered a major breakthrough with respect to the development of novel regenerative therapies and combine the advantages of adult and embryonic stem cells, namely, the availability of an autologous, ethically nonproblematic cell source with high potential for proliferation and differentiation into all cell lineages of interest. However, evaluation of novel cellular therapies in preclinical large-animal models and patients is currently hampered by the lack of suitable imaging approaches that allow long-term monitoring of viable transplanted cells. The present study was therefore designed to evaluate sodium iodide symporter transgene imaging as a novel approach to follow human induced pluripotent stem cell derivatives in a pig model of myocardial infarction. For the first time, our study demonstrates the usefulness of a sodium iodide symporter transgene for longitudinal in vivo tracking of survival, engraftment, and distribution of cellular grafts in a large-animal model with the use of single photon emission tomographic/computed tomographic imaging. Moreover, for the first time we demonstrate long-term survival and differentiation of human induced pluripotent stem cells in a preclinical pig model of myocardial infarction. The applied 3-dimensional hybrid imaging protocol enables combined assessment of cardiac anatomy and myocardial perfusion and monitoring of donor cell survival, proliferation, and distribution within 1 imaging modality. The developed approach will contribute to further optimization of novel cardiovascular cell-based treatment strategies and is of utmost importance for careful in vivo monitoring of associated risks such as potential tumor or teratoma formation.
Conclusions-This study describes for the first time the feasibility of repeated long-term in vivo imaging of viability and tissue distribution of cellular grafts in large animals. Moreover, this is the first report demonstrating vascular differentiation and long-term engraftment of hiPSCs in a large-animal model of myocardial infarction. NIS poshiPSCs represent a valuable tool to monitor and improve current cellular treatment strategies in clinically relevant animal models.
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Safety and Efficacy of Allogeneic Cell Therapy in Infarcted Rats Transplanted With Mismatched Cardiosphere-Derived Cells
Summary-Cardiosphere-derived cells (CDCs) are an attractive cell type for cardiomyoplasty after myocardial infarction, and autologous CDCs are already being tested clinically in the CArdiosphereDerived aUtologous stem CElls to reverse ventricUlar dySfunction (CADUCEUS) trial. Autologous therapy avoids immunologic rejection but necessitates patient-specific tissue harvesting, cell processing, and quality control, resulting in 3-to 6-week delays to therapy and possible variations in cell potency related to patient age and comorbidities. The use of universal donor (allogeneic) cells, if safe and effective, would obviate such limitations; however, immune rejection may limit effectiveness regardless of whether it poses safety hazards. Thus, we compared syngeneic and allogeneic CDC transplantation in infarcted rats from immunologically mismatched inbred strains. We demonstrate that allogeneic CDC therapy without immunosuppression is safe and induces only a mild transient local response without signs of systemic immunogenicity. Despite lower long-term engraftment compared with syngeneic cells, allogeneic CDCs produce similar structural and functional beneficial effects (which persist at least 6 months after transplantation). The benefits are due to stimulation of endogenous repair mechanisms and regrowth of recipient heart tissue rather than formation of new donor-derived myocardium. In practice, the present work opens up a new treatment paradigm: CDCs could be grown in large numbers from allogeneic heart tissue in a central facility under strict quality control and banked for future use, enabling safe and effective myocardial repair in a timely, cost-efficient manner. This work motivates the testing of allogeneic human CDCs as a potential clinical product for cellular cardiomyoplasty.
Conclusions-Allogeneic CDC transplantation without immunosuppression is safe, promotes cardiac regeneration, and improves heart function in a rat myocardial infarction model, mainly through stimulation of endogenous repair mechanisms. The indirect mechanism of action rationalizes the persistence of benefit despite the evanescence of transplanted cell survival. This work motivates the testing of allogeneic human CDCs as a potential off-the-shelf product for cellular cardiomyoplasty. Summary-Pulmonary transplantation recipients are a very specific population. They are generally younger and have fewer cardiovascular disease risk factors compared with patients undergoing other types of thoracic surgery. Therefore, the incidence of postoperative atrial fibrillation (AF), its clinical course, its treatment effectiveness, as well as the risk factors for AF are likely to differ in this highly selected population. In this large single-center series, we found that postoperative AF occurred in 29% of patients, similar to what is expected after other types of thoracic surgeries. AF was more likely to occur with complications such as pneumonia, mediastinitis, and bronchial dehiscence and was not an independent risk factor for mortality. Pharmacological or electrical therapy for rhythm or rate control was required in almost all patients. AF was largely benign and transient, with only 1 patient remaining in AF at discharge. Age, bilateral lung transplantation, and a history of AF before the transplantation were found to be independently associated with an increased incidence of postoperative AF. Pulmonary vein disconnection does not appear to reduce the incidence of AF, at least in the short term.
Conclusions-AF is fairly common after pulmonary transplantation, transient, and relatively benign. It is not independently associated with increased in-hospital mortality. Most patients return to sinus rhythm before discharge. Age, prior AF, and bilateral transplantation increase the risk of postoperative AF.
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How Small Is Too Small? A Systematic Review of Center Volume and Outcome After Cardiac Transplantation
Summary-Registry studies have demonstrated an association between center volume and outcome after cardiac transplantation. The number of cardiac transplants performed worldwide is static and low-volume heart transplant centers are common. There is a consistent association between center volume and posttransplant mortality across national and international registry studies. However, this association is less strong than other important variables such as ischemic time, donor age, or preoperative recipient clinical status. The existence of a minimum acceptable center volume is unproven, but analysis by volume category suggests that centers performing under 10 to 12 heart transplants per year may have higher mortality than centers performing >12 transplants per year.
Conclusions-There is a relationship between center volume and mortality in heart transplantation. The existence of a minimum acceptable center volume or threshold is unproven. However, a level of 10 to 12 heart transplants per year corresponds to the upper limit of low-volume categories that may have relatively higher mortality. It is not known whether outcomes for patients treated in low-volume transplant centers would be improved by reorganizing centers to ensure volumes in excess of 10 to 12 heart transplants per year. Summary-Cardiac transplantation has become the definitive treatment for eligible patients with end-stage cardiovascular disease, with durable 10-and 20-year outcomes. However, the immunosuppressive regimen that facilitates long-term positive outcomes is also responsible for chronic ill effects, including hypertension, weight gain, and malignancies. In the Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) trial, the authors report on the first prospective, randomized effort to compare conventional dual-drug immunosuppression with single-drug therapy. In both study groups, corticosteroids were discontinued within the first 2 months, which was well tolerated. The authors report excellent outcomes, with a median of 3 years (range, 1 to 5 years) of follow-up, although the trial was limited to 150 patients at 2 centers. The importance of this trial is that it shows that immunosuppression can be reduced in a prospective fashion, allowing some patients to take only a single antirejection medication. In addition, the fact that corticosteroids were safely discontinued in all trial participants suggests that potentially this class of medication may be a less necessary part of the long-term treatment of these patients.
Conclusions-Addition of mycophenolate to single-agent immunosuppression did not provide an advantage over single-agent immunosuppression in terms of rejection, allograft vasculopathy, or 3-year survival. Corticosteroids, which have traditionally been a mainstay of therapy, were successfully discontinued in all patients. These conclusions are tempered by the limited statistical power associated with a sample size of only 150 patients.
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Cardiac Allograft Function During the First Year after Transplantation in Rejection-Free Children and Young Adults
Summary-Heart transplantation (HT) is an established therapy in children with end-stage heart failure. Although severe early graft dysfunction after HT is rare, mild ventricular dysfunction is common even without rejection and may persist for years. Pulsed-wave tissue Doppler imaging (PW-TDI) is geometry-independent and allows quantification of both left ventricular and right ventricular (RV) function during systole and diastole. In this study, we analyzed serially performed PW-TDI studies in 44 pediatric HT recipients (median age at transplant 7.3 years) who remained rejection-free during the first year post-transplant to investigate the natural history of recovery of ventricular function. We used data from PW-TDI studies in 380 healthy children to transform patient data into age-adjusted z scores to allow better interpretation of raw PW-TDI data in the study children. We found biventricular systolic and diastolic dysfunction early after HT with most significant impairment in RV systolic function and RV and left ventricular early-diastolic filling. Although other aspects of left ventricular and RV function normalized in 6 to 9 months, RV systolic function remained abnormal 1-year post-transplant. Serial cardiac catheterization studies showed that RV and left ventricular filling pressures were elevated early after HT and declined gradually during the first year. These findings provide important insights into the natural history of recovery of biventricular function in pediatric HT recipients and improve our understanding of RV dysfunction in these patients. We suggest that a better understanding of ventricular function in rejection-free patients may also help in developing a PW-TDIbased rejection-surveillance protocol in pediatric HT recipients.
Conclusions-Pediatric HT recipients have biventricular dysfunction using pulsed-wave tissue Doppler imaging early after HT with most significant impairment in RV systolic function and RV and LV early-diastolic filling. Although other aspects of LV and RV function normalize in 6 to 9 months, RV systolic function remains abnormal 1 year-post-transplant. Summary-Despite major advances in clinical organ transplantation, the late outcome of transplanted patients is impaired by chronic rejection, which mainly affects the blood vessels of the transplanted organ, so-called transplant vasculopathy. This pathology is characterized by a progressive neointimal hyperplasia with proliferating smooth muscle cells and secretion of extracellular matrix, leading to arterial stenosis and ischemic failure of the allograft. The mechanism of transplant vasculopathy is only partly understood and involves cellular and humoral immune responses that target the transplanted organ. We wanted to elucidate the manner in which the humoral immune response contributes to transplant vasculopathy. In vitro studies indicated that anti-HLA class I antibodies are mitogenic for human smooth muscle cells through a mechanism that involves matrix metalloproteinases and neutral sphingomyelinase-2. Pharmacological inhibitors of metalloproteinases (batimastat and Ro28-2653) and of neutral sphingomyelinase-2 (GW4869) blocked signaling through these pathways. To explore these findings in vivo, we developed a model for human transplant vasculopathy, consisting of human mesenteric arterial segments grafted into severe combined immunodeficiency/ beige mice. Mice injected weekly with monoclonal antibody toward HLA class I developed neointimal thickening of the grafted human arterial segment, whereas mice injected with an irrelevant antibody accepted the graft permanently. Treatment of the animals with Ro28-2653 and GW4869 led to a net reduction of the intimal hyperplasia induced by monoclonal antibody in the human mesenteric artery grafts. These data highlight a crucial role for metalloproteinases and neutral sphingomyelinase-2 in vasculopathy generated by a humoral immune response, opening new therapeutic perspectives for preventing this pathology, in addition to treatment with conventional immunosuppression.
Conclusions-These data highlight a crucial role for matrix metalloproteinase-2 and neutral sphingomyelinase-2 in vasculopathy triggered by a humoral immune response and open new perspectives for preventing transplant vasculopathy with the use of matrix metalloproteinase and neutral sphingomyelinase inhibitors, in addition to conventional immunosuppression. 21 
